drugset
drugset / Trial / NCT00868127

Safety of Lapaquistat Acetate in Subjects With Hypercholesterolemia

NCT00868127 ↗

Phase 3 Completed 574 enrolled Takeda
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the long-term safety of lapaquistat acetate, once daily (QD), as monotherapy or in combination with other lipid-lowering agents in Subjects with Hypercholesterolemia.

Timeline

Start
2005-12
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Lapaquistat acetate Small molecule 100 mg Oral

Indications

hyperlipidemia